LSBC.F Share Price Performance
US$0.77
-3.02 (-79.68%)
Price US$0.77
Share PriceUS$0.77
Revenues Working Against LakeShore Biopharma Co., Ltd's (NASDAQ:LSB) Share Price Following 27% Dive
Jan 24
LakeShore Biopharma Co., Ltd Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 1 Fair Values set on narratives written by author
LSBC.F Community Narratives
There are no narratives available yet.
LakeShore Biopharma Co., Ltd Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -2.43
- Gross Margin
- 82.48%
- Net Profit Margin
- -16.26%
- Debt/Equity Ratio
- 82.8%
LakeShore Biopharma Co., Ltd Competitors
Snowflake Analysis
About LSBC.F
- Founded
- 1994
- Employees
- 573
- CEO
- WebsiteView website
LakeShore Biopharma Co., Ltd, a biopharmaceutical company, discovers, develops, manufactures, commercializes, and sells vaccines and therapeutic biologics for infectious diseases and cancer. Its product pipeline includes YSJA, a conventional rabies vaccine, which is in marketed stage; PIKA, a rabies vaccine, which is in phase I/III and preclinical trials for the treatment of rabies virus; PIKA YS-ON-001, an immuno-oncology therapeutic candidate that is in phase I trial for the treatment of pancreatic and hepatocellular cancer; PIKA YS-HBV-001, a hepatitis B vaccine, which is in phase I trial; PIKA YS-HBV-002, an immune-therapy vaccine that is in preclinical trial for the treatment of chronic HBV infection; and PIKA YS-ON-001 and PIKA Influenza Vaccine, which are in preclinical trials. The company was formerly known as YS Biopharma Co., Ltd. and changed its name to LakeShore Biopharma Co., Ltd in May 2024. LakeShore Biopharma Co., Ltd was founded in 1994 and is based in Beijing, China.
Market Insight
Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading
Chinese Market Performance
- 7 Days: -0.2%
- 3 Months: 16.4%
- 1 Year: 29.8%
- Year to Date: 26.3%
In the last week, the market has stayed flat, however the Utilities sector stood out, gaining 3.3%. More promisingly, the market is up 30% over the past year. Looking forward, earnings are forecast to grow by 26% annually. Market details ›